The company's FDA-cleared software assists radiologists in interpreting MRI images of the prostate, and their screening equipment uses AI to analyze MRI scans for prostate cancer in a single session, with plans to expand to up to 13 organs. Ezra aims to make early cancer detection more accessible and affordable by developing screening technologies that are faster, cheaper, and more accurate.